ASK DIS: Daflon: Renal Dose

Monday, March 14, 2016

Availability:

Recommendation:

Micronized diosmin/hesperidin has undergone extensive safety evaluation, and appears to be essentially free from toxicological risk.
Maximum safe dosages in individuals with severe hepatic or renal disease are not known
Renal and hepatic impairment are not in the caution/contraindicated label
No evidence of dosing adjustment in haemodialysis

Based on Diosmin

In multiple clinical studies, the effects of diosmin in VASCULERA on blood chemistry as well as hepatic and renal function were compared to placebo in healthy subjects and patients with chronic venous insufficiency
No changes were noted in most studies with the exception of statistically significant decreases in creatinine levels in subjects taking diosmin in several clinical trials.

Supporting evidence

Lack of studies and evidence
Between January 2004 and October 2012, 1 individuals taking DAFLON (DIOSMIN) reported RENAL FAILURE ACUTE to the FDA
Based on some available studies, diosmin/hesperidin was used for studies of nephro-protective function in rats treated with Amphotericin B, showing an antioxidant protective effect on the kidneys.
In another study, Diosmin reduces CaOx deposition and the degeneration of glomeruli and tubules in a rat model of nephrolithiasis

References:

ASK DIS